BCRX Earnings Biocryst Pharmaceuticals Inc
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–32 of 32
| Q2 2026 | 2026-06-30 | 0.30 | 2026-08-05 | 10-Q |
| Q1 2026 | 2026-03-31 | -2.98 | 2026-05-06 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | 1.13 | 2026-02-26 | 10-K |
| FY 2025 | 2025-12-31 | 1.21 | 2026-02-26 | 10-K |
| Q3 2025 | 2025-09-30 | 0.06 | 2025-11-04 | 10-Q |
| Q2 2025 | 2025-06-30 | 0.02 | 2025-08-05 | 10-Q |
| Q1 2025 | 2025-03-31 | 0.00 | 2025-05-06 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -0.13 | 2025-02-25 | 10-K |
| FY 2024 | 2024-12-31 | -0.43 | 2025-02-25 | 10-K |
| Q3 2024 | 2024-09-30 | -0.07 | 2024-11-05 | 10-Q |
| Q2 2024 | 2024-06-30 | -0.06 | 2024-08-06 | 10-Q |
| Q1 2024 | 2024-03-31 | -0.17 | 2024-05-07 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -0.31 | 2024-02-27 | 10-K |
| FY 2023 | 2023-12-31 | -1.18 | 2024-02-27 | 10-K |
| Q3 2023 | 2023-09-30 | -0.19 | 2023-11-08 | 10-Q |
| Q2 2023 | 2023-06-30 | -0.40 | 2023-08-07 | 10-Q |
| Q1 2023 | 2023-03-31 | -0.28 | 2023-05-08 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -0.38 | 2023-02-27 | 10-K |
| FY 2022 | 2022-12-31 | -1.33 | 2023-02-27 | 10-K |
| Q3 2022 | 2022-09-30 | -0.23 | 2022-11-04 | 10-Q |
| Q2 2022 | 2022-06-30 | -0.32 | 2022-08-05 | 10-Q |
| Q1 2022 | 2022-03-31 | -0.40 | — | — |
| FY 2021 | 2021-12-31 | -1.03 | — | — |
| Q3 2021 | 2021-09-30 | -0.33 | — | — |
| Q2 2021 | 2021-06-30 | -0.24 | — | — |
| FY 2020 | 2020-12-31 | -1.09 | — | — |
| Q2 2016 | 2016-06-30 | -0.22 | 2016-08-08 | 10-Q |
| Q4 2015 | 2015-12-31 | -0.25 | 2016-02-26 | 10-K |
| Q3 2016 | 2015-09-30 | -0.20 | — | — |
| Q2 2015 | 2015-06-30 | 0.06 | 2015-08-07 | 10-Q |
| Q1 2016 | 2015-03-31 | -0.21 | — | — |
| Q2 2014 | 2014-06-30 | -0.23 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.